$Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review$

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review

Introduction: With an increase in number of cases of relapsed or refractory multiple myeloma (RRMM), scientist have discovered various combination of medications among which one is daratumumab, Daratumumab is a mono-clonal antibody which attacks CD-38 markers present in abundance on the surface of m...

Full description

Bibliographic Details
Main Authors:	Abubakar Tauseef, Maryam Zafar, Peter Silberstein, Joseph Nahas, Thomas Frederickson, Faith Abodunrin, Anum Abbas, Wafa Arshad, Noman Lateef, Hussain Rangoonwala, Sara Albagoush, Mohsin Mirza
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Journal of Family Medicine and Primary Care
Subjects:	daratumumab literature multiple myeloma refractory relapsed role
Online Access:	http://www.jfmpc.com/article.asp?issn=2249-4863;year=2022;volume=11;issue=6;spage=2648;epage=2655;aulast=Tauseef

Similar Items

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series
by: Faouzi Djebbari, et al.
Published: (2022-12-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
by: Dima D, et al.
Published: (2020-08-01)

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
by: Atakan Tekinalp, et al.
Published: (2023-12-01)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
by: Ludovica Fucci, et al.
Published: (2022-01-01)

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure
by: Irene Zamanillo, et al.
Published: (2023-08-01)

Daratumumab: A drug with transfusion dilemma
by: Amit Kumar Biswas, et al.
Published: (2023-01-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model
by: Niels vanNieuwenhuijzen, et al.
Published: (2024-02-01)

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
by: Lisa B. Leypoldt, et al.
Published: (2023-09-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment
by: Audrey Abecassis, et al.
Published: (2022-08-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Daratumumab for the Treatment of Multiple Myeloma
by: Torben Plesner, et al.
Published: (2018-06-01)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020-11-01)

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
by: Rafael Ríos-Tamayo, et al.
Published: (2023-12-01)

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA
by: V. V. Ryzhko, et al.
Published: (2017-11-01)

Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta‐analysis
by: Congcong Cao, et al.
Published: (2021-08-01)

Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
by: Tracy King, et al.
Published: (2018-01-01)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
by: Francesca Cottini, et al.
Published: (2021-02-01)

Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
by: Yuichi Horigome, et al.
Published: (2024-03-01)

Daratumumab: The perplexity in immunohematology with emerging horizons in myeloma therapy
by: Soma Agrawal, et al.
Published: (2020-01-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
by: Lakshmi Yarlagadda, et al.
Published: (2021-08-01)

Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients
by: Alessandro Gozzetti, et al.
Published: (2020-12-01)

Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
by: Vincenzo Sammartano, et al.
Published: (2022-03-01)

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Lu Ye, et al.
Published: (2023-12-01)

Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
by: Ashraf Kakoo, et al.
Published: (2021-06-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
by: Evangelos Terpos, et al.
Published: (2022-06-01)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
by: Hee Jeong Cho, et al.
Published: (2023-03-01)

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma
by: Nicolas Stocker, et al.
Published: (2020-03-01)

Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study
by: Evangelos Terpos, et al.
Published: (2021-10-01)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
by: Celine Berthon, et al.
Published: (2020-01-01)